Early PET scan for head and neck cancer on immunotherapy
Part of Cancer clinical trials.
This trial uses a special PET/CT scan early in treatment to see if first-line immunotherapy is working for people with recurrent or metastatic head and neck cancer. It aims to learn if early response can predict outcomes and help guide care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck cancer that has come back or spread and cannot be removed by surgery or treated with radiation.
- You are about to receive your first systemic treatment for this stage of cancer (immunotherapy alone).
- Your tumor must have a PD-L1 level of at least 1 (tested from a biopsy).
- You do not have any medical condition that would make it unsafe to take immune checkpoint inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to look at head and neck cancer cells before treatment. It may help doctors learn more about your cancer and decide if different treatments could work better for you.
This study uses PET-CT scans (a type of imaging that highlights active cancer cells) in people with a specific kind of head and neck cancer. The goal is to see how well the first scan identifies tumors that should be checked again with a second scan, to better guide care with radiotherapy.
This trial uses a new imaging agent called [18F]-AraG to see how well it can show head and neck cancers before and after standard radiation therapy. If you have advanced cancer of the throat or voice box that can't be surgically removed, this scan may help doctors understand your cancer better.
This trial tests a special PET scan that tracks immune activity to see if it can help monitor how well immunotherapy is working in people with various cancers. It is for patients about to start immunotherapy for the first time.
This study collects blood and tumor tissue samples to analyze biological markers in patients with advanced head and neck squamous cell carcinoma before starting immunotherapy. The goal is to better understand how these markers relate to treatment response.
This study is looking for people with advanced head and neck cancer who have already received immunotherapy plus chemotherapy as their first treatment. Researchers will study your tumor tissue and proteins to find better ways to use immunotherapy.
Hear when a new Head & Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.